Topoisomerase II and the etiology of chromosomal translocations

DNA Repair

Volumn 5, Issue 9-10, 2006, Pages 1093-1108

  Felix, Carolyn A ^a,b   Kolaris, Christos P ^a   Osheroff, Neil ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epipodophyllotoxin, Topoisomerase II; Leukemia; MLL gene; Translocation

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAFFEINE; DACTINOMYCIN; DAIDZEIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ELLAGIC ACID; EPIRUBICIN; ETOPOSIDE; GENISTEIN; MITOXANTRONE; QUERCETIN; QUINONE DERIVATIVE; TENIPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHROMOSOME TRANSLOCATION; DNA DAMAGE; DNA POLYMORPHISM; DNA REPAIR; GENE CLUSTER; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; MOLECULAR CLONING; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOLID TUMOR;

ANTIBIOTICS, ANTINEOPLASTIC; BASE SEQUENCE; DNA TOPOISOMERASES, TYPE II; HUMANS; INFANT; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECOMBINATION, GENETIC; TOPOISOMERASE II INHIBITORS; TRANSLOCATION, GENETIC;

PROTEA;

EID: 33747892853     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2006.05.031     Document Type: Article

References (219)

1. Wang J.C. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Quart. Rev. Biophys. 31 2 (1998) 107-144
2. Burden D.A., and Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochimica. et. Biophysica. Acta 1400 1-3 (1998) 139-154
3. Berger J.M. Structure of DNA topoisomerases. Biochimia. et. Biophysica. Acta 1400 (1998) 3-18
4. Fortune J.M., and Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog. Nucleic. Acid Res. Molecular Biol. 64 (2000) 221-253
5. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70 (2001) 369-413
6. Baldwin E.L., and Osheroff N. Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents 5 4 (2005) 363-372
7. Drake F.H., Zimmerman J.P., McCabe F.L., et al. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J. Biol. Chem. 262 34 (1987) 16739-16747
8. Drake F.H., Hofmann G.A., Bartus H.F., Mattern M.R., Crooke S.T., and Mirabelli C.K. Biochemical and pharmacological properties of pl70 and pl80 forms of topoisomerase II. Biochemistry 28 20 (1989) 8154-8160
9. Tsai-Pflugfelder M., Liu L.F., Liu A.A., et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc. National Academy Sci. United States America 85 19 (1988) 7177-7181
10. Jenkins J.R., Ayton P., Jones T., et al. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 20 21 (1992) 5587-5592
11. Tan K.B., Dorman T.E., Falls K.M., et al. Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res. 52 1 (1992) 231-234
12. Austin C.A., and Marsh K.L. Eukaryotic DNA topoisomerase IIβ. Bioessays 20 (1998) 215-226
13. Nitiss J.L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta 1400 1-3 (1998) 63-81
14. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 3 6 (2002) 430-440
15. Dereuddre S., Delaporte C., and Jacquemin-Sablon A. Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res. 57 19 (1997) 4301-4308
16. Grue P., Grasser A., Sehested M., et al. Essential mitotic functions of DNA topoisomerase IIβ are not adopted by topoisomerase IIβ in human H69 cells. J. Biol. Chem. 273 50 (1998) 33660-33666
17. Woessner R.D., Mattern M.R., Mirabelli C.K., Johnson R.K., and Drake F.H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2 (1991) 209-214
18. Heck M.M., and Earnshaw W.C. Topoisomerase II: A specific marker for cell proliferation. J. Cell Biol. 103 6 Pt 2 (1986) 2569-2581
19. Heck M.M., Hittelman W.N., and Earnshaw W.C. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. National Academy Sci. United States America 85 (1988) 1086-1090
20. Bauman M.E., Holden J.A., Brown K.A., Harker W.G., and Perkins S.L. Differential immunohistochemical staining for DNA topoisomerase II β and β in human tissues and for DNA topoisomerase II β in non-Hodgkin's lymphomas. Mod. Pathol. 10 3 (1997) 168-175
21. Sullivan D.M., Latham M.D., and Ross W.E. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res. 47 (1987) 3973-3979
22. Hsiang Y.H., Wu H.Y., and Liu L.F. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res. 48 11 (1988) 3230-3235
23. Isaacs R.J., Davies S.L., Sandri M.I., Redwood C., Wells N.J., and Hickson I.D. Physiological regulation of eukaryotic topoisomerase II. Biochim. Biophys. Acta 1400 1-3 (1998) 121-137
24. Carpenter A.J., and Porter A.C. Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Mol. Biol. Cell 15 12 (2004) 5700-5711
25. Sander M., and Hsieh T. Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster. J. Biol. Chem. 258 13 (1983) 8421-8428
26. Liu L.F., Rowe T.C., Yang L., Tewey K.M., and Chen G.L. Cleavage of DNA by mammalian DNA topoisomerase II. J. Biol. Chem. 258 (1983) 15365-15370
27. Rowe T.C., Chen G.L., Hsiang Y.H., and Liu L.F. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res. 46 (1986) 2021-2026
28. Horowitz D.S., and Wang J.C. Mapping the active site tyrosine of Escherichia coli DNA gyrase. J. Biol. Chem. 262 11 (1987) 5339-5344
29. Worland S.T., and Wang J.C. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J. Biol. Chem. 264 8 (1989) 4412-4416
30. Zechiedrich E.L., Christiansen K., Andersen A.H., Westergaard O., and Osheroff N. Double- stranded DNA cleavage religation reaction of eukaryotic topoisomerase II: Evidence for a nicked DNA intermediate. Biochemistry 28 (1989) 6229-6236
31. Felix C.A. Therapy-Related Leukemias. In: Pui C.-H. (Ed). Childhood Leukemias. second ed. (2006), Cambridge University Press, Cambridge, UK 774-804
32. Felix C.A. Secondary Myelodysplasia/Acute Myeloid Leukemia. In: Young N.S., Gerson S.L., and High K.A. (Eds). Clinical Hematology. first ed. (2006), Elsevier, Philadelphia 374-388
33. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 65 (1996) 635-692
34. Baguley B.C., and Ferguson L.R. Mutagenic properties of topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400 1-3 (1998) 213-222
35. Kaufmann S.H. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochimica. et. Biophysica. Acta 1400 1-3 (1998) 196-211
36. Felix C.A. Secondary leukemias induced by topoisomerase targeted drugs. Biochimica. et. Biophysica. Acta 1400 1-3 (1998) 233-255
37. Holm C., Covey J.M., Kerrigan D., and Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49 22 (1989) 6365-6368
38. D'Arpa P., Beardmore C., and Liu L. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50 (1990) 6919-6934
39. Howard M., Neece S., Matson S., and Kreuzer K. Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. Proc. Natl. Acad. Sci. USA 91 (1994) 12031-12035
40. Felix C.A. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol. 36 5 (2001) 525-535
41. Kreuzer K.N., and Cozzarelli N.R. Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J. Bacteriol. 140 2 (1979) 424-435
42. Hande K.R. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta 1400 1-3 (1998) 173-184
43. Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J. Cancer 34 10 (1998) 1514-1521
44. Pommier Y. DNA Topoisomerase II inhibitors. In: Teicher B.A. (Ed). Cancer Therapeutics: Experimental and Clinical Agents (1997), Humana Press, Totowa, New Jersey 153-174
45. Li T.K., and Liu L.F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 53-77
46. Andoh T., and Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochimica. et. Biophysica. Acta 1400 (1998) 155-194
47. Larsen A.K., Escargueil A.E., and Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther. 99 2 (2003) 167-181
48. Strick R., Strissel P.L., Borgers S., Smith S.L., and Rowley J.D. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukaemia. Proc. Natl. Acad. Sci. USA 97 9 (2000) 4790-4795
49. Lindsey Jr. R.H., Bromberg K.D., Felix C.A., and Osheroff N. 1,4-Benzoquinone Is a Topoisomerase II Poison. Biochemistry 43 23 (2004) 7563-7574
50. Lindsey R.H., Bender R.P., and Osheroff N. Stimulation of topoisomerase II-mediated DNA cleavage by benzene metabolites. Chem. Biol. Interact. 153-154 (2005) 197-205
51. Lindsey Jr. R.H., Bender R.P., and Osheroff N. Effects of benzene metabolites on DNA cleavage mediated by human topoisomerase II alpha: 1,4-hydroquinone is a topoisomerase II poison. Chem. Res. Toxicol. 18 4 (2005) 761-770
52. Shin C.G., Strayer J.M., Wani M.A., and Snapka R.M. Rapid evaluation of topoisomerase inhibitors: caffeine inhibition of topoisomerases in vivo. Teratogen. Carinog. Mutagen. 10 (1990) 41-52
53. Snyder R.D., and Gillies P.J. Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells. Environ. Molecular Mutagenesis 40 4 (2002) 266-276
54. Constantinou A., Stoner G.D., Mehta R., Rao K., Runyan C., and Moon R. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro. Nutrition Cancer 23 2 (1995) 121-130
55. Sabourin M., and Osheroff N. Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res. 28 9 (2000) 1947-1954
56. Kingma P.S., Corbett A.H., Burcham P.C., Marnett L.J., and Osheroff N. Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II. J. Biol. Chem. 270 (1995) 21441-21444
57. Kingma P.S., Greider C.A., and Osheroff N. Spontaneous DNA lesions poison human topoisomerase IIβ and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochemistry 36 (1997) 5934-5939
58. Kingma P.S., and Osheroff N. Apurinic sites are position-specific topoisomerase II poisons. J. Biol. Chem. 272 (1997) 1148-1155
59. Velez-Cruz R., Riggins J.N., Daniels J.S., et al. Exocyclic DNA lesions stimulate DNA cleavage mediated by human topoisomerase IIalpha in vitro and in cultured cells. Biochemistry 44 10 (2005) 3972-3981
60. Seeker-Walker L.M., Stewart E.L., and Todd A. Acute lymphoblastic leukaemia with t(4;1 1) follows neuroblastoma: a late effect of treatment. Med. Pediatr. Oncol. 13 (1985) 48-50
61. Corbett A., and Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol. 6 (1993) 585-597
62. Ratain M.J., Kaminer L.S., Bitran J.D., et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 70 (1987) 1412-1417
63. Pui C.H., Ribeiro R.C., Hancock M.L., et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N. Engl. J. Med. 325 24 (1991) 1682-1687
64. Pui C.-H., Hancock M.L., Raimondi S.C., et al. Myeloid neoplasia in children treated for solid tumours. Lancet 336 (1990) 417-421
65. Pui C.-H., Behm F.G., Raimondi S.C., et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N. Engl. J. Med. 321 (1989) 136-142
66. Winick N., McKenna R.W., Shuster J.J., et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J. Clin. Oncol. 11 (1993) 209-217
67. Chak L.Y., Sikic B.I., Tucker M.A., Horns Jr. R.C., and Cox R.S. Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung. J. Clin. Oncol. 2 (1984) 385-390
68. Johnson D.H., Porter L.L., List A.F., Hande K.R., Hainsworth J.D., and Greco F.A. Acute nonlymphocytic leukemia after treatment of small cell lung cancer. Am. J. Med. 81 (1986) 962-968
69. Weh H.J., Kabisch H., Landbeck G., and Hossfeld D.K. Translocation (9;11) (p21q23) in a child with acute monoblastic leukemia following 2 1/2 years after successful chemotherapy for neuroblastoma. J. Clin. Oncol. 4 (1986) 1518-1520
70. Albain K.S., Le Beau M.M., Ullirsch R., and Schumacher H. Implications of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation. Genes Chromosomes Cancer 2 (1990) 53-58
71. Verdeguer A., Ruiz J.G., Ferris J., et al. Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide. Med. Pediatr. Oncol. 20 (1992) 48-52
72. Heyn R., Khan F., Ensign L.G., et al. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III An interim report. Med. Pediatr. Oncol. 23 (1994) 99-106
73. DeVore R., Whitlock J., Hainsworth J.D., and Johnson D.H. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. Ann. Intern. Med. 110 (1989) 740-742
74. Whitlock J.A., Greer J.P., and Lukens J.N. Epipodophyllotoxin-related leukemia: identification of a new subset of secondary leukemia. Cancer 68 (1991) 600-604
75. Zeimet A.G., Thaler J., Abfalter E., Marth C., and Dapunt O. Secondary leukaemias after etoposide. Lancet 340 (1992) 379-380
76. Hawkins M.M. Secondary leukaemia after epipodophyllotoxins. Lancet 338 (1991) 1408
77. Hawkins M.M., Kinnier-Wilson L.M., Stovall M.A., et al. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. Br. Med. J. 304 (1992) 951-958
78. Pedersen-Bjergaard J., Philip P., Larsen S.O., Jensen G., and Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76 (1990) 1083-1091
79. Nichols C.R., Breeden E.S., Loehrer P.J., Williams S.D., and Einhorn L.H. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J. Natl. Cancer Inst. 85 (1993) 36-40
80. Bajorin D.F., Motzer R.J., Rodriguez E., Murphy B., and Bosl G.J. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J. Natl. Cancer Inst. 85 (1993) 60-62
81. Pedersen-Bjergaard J., Daugaard G., Hansen S.W., Philip P., Larsen S.O., and Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338 (1991) 359-363
82. Donatini B., and Krupp P. Secondary pre-leukaemia and etoposide. Lancet 338 (1991) 1269
83. Rose V.L., Keppen M.D., Eichner E.R., Pitha J.V., and Murray J.L. Acute leukemia after successful chemotherapy for oat cell carcinoma. Am. J. Clin. Pathol. 79 (1983) 122-124
84. Bokemeyer C., and Schmoll H.-J. Secondary neoplasms following treatment of malignant germ cell tumors. J. Clin. Oncol. 11 (1993) 1703-1709
85. Rivera G.K., Pui C.H., Santana V.M., Pratt C.B., and Crist W.M. Epipodophyllotoxins in the treatment of childhood cancer. Cancer Chemother. Pharmacol. 34 Suppl (1994) S89-S95
86. Giaccone G. Teniposide alone and in combination chemotherapy in small cell lung cancer. Semin. Oncol. 19 2 Suppl 6 (1992) 75-80
87. Giaccone G., Splinter T.A., Kirkpatrick A., Dalesio O., van Zandwijk N., and McVie J.G. The European Organization for Research and Treatment of Cancer experience with teniposide: preliminary results of a randomized study in non-small cell lung cancer. Semin. Oncol. 19 2 Suppl. 6 (1992) 98-102
88. Muggia F.M. Teniposide: overview of its therapeutic potential in adult cancers. Cancer Chemother. Pharmacol. 34 Suppl. (1994) S127-S133
89. Hirsch F.R., Dombernowsky P., and Hansen H.H. Treatment of small cell lung cancer: the Copenhagen experience. Anticancer Res 14 lB (1994) 317-319
90. Muggia F.M., and Kelley S.L. Teniposide in adult solid tumors: a historical perspective. Semin. Oncol. 19 2 Suppl. 6 (1992) 43-50
91. Smith M.A., Rubenstein L., Anderson J.R., et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J. Clin. Oncol. 17 2 (1999) 569-577
92. Weh H.J., Kabisch H., Landbeck G., and Hossfeld D.K. Translocation (9;11) (p21;q23) in a child with acute monoblastic leukemia following 2 and 1/2 years after successful chemotherapy for neuroblastoma. J. Clin. Oncol. 4 10 (1986) 1518-1520
93. Kreissman S.G., Gelber R.D., Cohen H.J., Clavell L.A., Leavitt P., and Sallan S.E. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer 70 (1992) 2208-2213
94. Pedersen-Bjergaard J., Sigsgaard T.C., Nielsen D., et al. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J. Clin. Oncol. 10 (1992) 1444-1451
95. Detourmignies L., Castaigne S., Stoppa A.M., et al. Therapy-related acute promyelocytic leukemia: a report on 16 cases. J. Clin. Oncol. 10 9 (1992) 1430-1435
96. Sandoval C., Pui C.H., Bowman L.C., et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J. Clin. Oncol. 11 6 (1993) 1039-1045
97. Atlas M., Head D., Behm F., et al. Cloning and sequence analysis of four t(9;11) therapy- related leukemia breakpoints. Leukemia 12 (1998) 1895-1902
98. Kushner B.H., Heller G., Cheung N.K., et al. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J. Clin. Oncol. 16 9 (1998) 3016-3020
99. Kushner B.H., Cheung N.K., Kramer K., Heller G., and Jhanwar S.C. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J. Clin. Oncol. 16 (1998) 3880-3889
100. Megonigal M.D., Cheung N.K., Rappaport E.F., et al. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc. Natl. Acad. Sci. USA 97 6 (2000) 2814-2819
101. Vicari A.M., Ciceri F., Folli F., et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis [letter]. Leukemia 12 3 (1998) 441-442
102. Pedersen-Bjergaard J., and Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 78 (1991) 1147-1148
103. Megonigal M.D., Rappaport E.F., Jones D.H., et al. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc. Natl. Acad. Sci. USA 94 (1997) 11583-11588
104. Crump M., Tu D., Shepherd L., Levine M., Bramwell V., and Pritchard K. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21 16 (2003) 3066-3071
105. Ratain M.J., Kaminer L.S., Bitran J.D., et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 70 5 (1987) 1412-1417
106. Pui C.H., Kalwinsky D.K., Schell M.J., Mason C.A., Mirro Jr. J., and Dahl G.V. Acute nonlymphoblastic leukemia in infants: clinical presentation and outcome. J. Clin. Oncol. 6 6 (1988) 1008-1013
107. Smith M.A., Rubenstein L., and Ungerleider R.S. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med. Pediatr. Oncol. 23 (1994) 86-98
108. Felix C.A., Hosier M.R., Winick N.J., Masterson M., Wilson A.E., and Lange B.J. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 85 (1995) 3250-3256
109. Beaumont M., Sanz M., Carli P.M., et al. Therapy-related acute promyelocytic leukemia. J. Clin. Oncol. 21 11 (2003) 2123-2137
110. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28 15 (1989) 6157-6160
111. Wassermann K., Markovits J., Jaxel C., Capranico G., Kohn K.W., and Pommier Y. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharmacol. 38 1 (1990) 38-45
112. Olney H.J., Mitelman F., Johansson B., Mrozek K., Berger R., and Rowley J.D. Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. Genes Chromosomes Cancer 33 4 (2002) 413-423
113. Pedersen-Bjergaard J., Andersen M.K., Christiansen D.H., and Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 99 6 (2002) 1909-1912
114. Thirman M.J., Gill H.J., Burnett R.C., et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N. Engl. J. Med. 329 (1993) 909-914
115. Rubin C.M., Arthur D.C., Woods W.G., et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood 78 (1991) 2982-2988
116. Rowley J.D., Vignon C., Gollin S.M., Rosenberg C.L., Wyandt H.E., and Milunsky A. Rearrangements involving chromosome band 11q23 in acute leukemia. N. Engl. J. Med. 334 (1996) 601-603
117. Rubnitz J.E., Behm F.G., and Downing J.R. 11q23 rearrangements in acute leukemia. Leukemia 10 (1996) 74-82
118. Pui C.-H., Relling M.V., Rivera G.K., et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 9 (1995) 1990-1996
119. Ayton P.M., and Cleary M.L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20 40 (2001) 5695-5707
120. Yokoyama A., Wang Z., Wysocka J., et al. Leukemia proto-oncoprotein MLL forms a SET 1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell Biol. 24 (2004) 5639-5649
121. Zeisig B.B., Milne T., Garcia-Cuellar M.P., et al. Hoxa9 and Meisl are key targets for MLL- ENL-mediated cellular immortalization. Mol. Cell Biol. 24 2 (2004) 617-628
122. Broeker P.L., Super H.G., Thirman M.J., et al. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 87 5 (1996) 1912-1922
123. Domer P.H., Head D.R., Renganathan N., Raimondi S.C., Yang E., and Atlas M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 9 (1995) 1305-1312
124. Lovett B.D., Lo Nigro L., Rappaport E.F., et al. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc. Natl. Acad. Sci. USA 98 (2001) 9802-9807
125. Raffini L.J., Slater D.J., Rappaport E.F., et al. Panhandle and reverse panhandle PCR enable cloning of der (11) and der (other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4 and CDK6. Proc. Natl. Acad. Sci. USA 99 (2002) 4568-4573
126. Langer T., Metzler M., Reinhardt D., et al. Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. Genes Chromosomes Cancer 36 4 (2003) 393-401
127. Whitmarsh R., Saginario C., Zhuo Y., et al. Reciprocal DNA topoisomerase II cleavage events at 5′-TATTA-3′ sequence in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Oncogene 22 (2003) 8448-8459
128. Sobulo O.M., Borrow J., Tomek R., et al. MLL is fused to CBP, a histone acetyltransferase, in therapy related acute myeloid leukemia with a t(11;16) (q23;p13.3). Proc. Natl. Acad. Sci. USA 94 (1997) 8732-8737
129. Germano G., Robinson B.W., and Felix C.A. Cryptic MLL, AF10, ARMC3 rearrangement in secondary AML creates ARMC3-MLL fusion that disrupts gene encoding armadillo repeats similar to major cancer genes. Blood (Proc ASH Annual Meeting) (2005)
130. Chaplin T., Jones L., Debernardi S., Hill A.S., Lillington D.M., and Young B.D. Molecular analysis of the genomic inversion and insertion of AF10 into MLL suggests a single-step event. Genes Chromosomes Cancer 30 2 (2001) 175-180
131. Kantarjian H.M., Keating M.J., Walters R.S., et al. The association of specific "favorable" cytogenetic abnormalities with secondary leukemia. Cancer 58 (1986) 924-927
132. Pedersen-Bjergaard J., Daugaard G., Hansen S.W., Philip P., Larsen S.O., and Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours [see comments]. Lancet 338 8763 (1991) 359-363
133. Quensel B., Kantarjian H., Pedersen-Bjergaard J., et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): A report on 25 cases and review of the literature. J. Clin. Oncol. 11 (1993) 2370-2379
134. Sandoval C., Pui C.-H., Bowman L.C., et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J. Clin. Oncol. 11 (1993) 1039-1045
135. Larson R.A., Le Beau M., Ratain M.J., and Rowley J.D. Balanced translocations involving chromosome bandsllq23 and 21q22 in therapy-related leukemia. Blood 79 (1992) 1892-1893
136. Rubin C.M., Larson R.A., Anastasi J., et al. t(3;21) (q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 76 (1990) 2594-2598
137. Nucifora G., Birn D.J., Espinosa III R., et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood 81 (1993) 2728-2734
138. Nucifora G., and Rowley J.D. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86 (1995) 1-14
139. Roulston D., Espinosa III R., Nucifora G., Larson R., Le Beau M.M., and Rowley J.D. CBFA2 (AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood 92 (1998) 2879-2885
140. Slovak M.L., Bedell V., Popplewell L., Arber D.A., Schoch C., and Slater R. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. Genes Chromosomes Cancer 33 4 (2002) 379-394
141. Raiker A., Green W., Shabaik A., and Perlin E. Acute promyelocytic leukemia following treatment of non-Hodgkin's lymphoma. Cancer 63 (1989) 1402-1406
142. Lopez-Andreu J.A., Ferris J., Verdeguer A., Esquembre C., Senent M.L., and Castel V. Secondary acute promyelocytic leukemia in a child treated with epipodophyllotoxins. Am. J. Periatr. Hematol./Oncol. 16 (1994) 384-386
143. Pedersen-Bjergaard J., Andersen M.K., and Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J. Clin. Oncol. 16 5 (1998) 1897-1898
144. Wiernick P.H., and Muse I.M. Acute promyelocytic leukemia after treatment of malignant glioma in a patient with Von Recklinghausen's disease: A case report and review of the literature. Leukemia 10 (1996) 178-191
145. Andersen M.K., Larson R.A., Mauritzson N., Schnittger S., Jhanwar S.C., and Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy- related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 33 4 (2002) 395-400
146. Pedersen-Bjergaard J., and Rowley J.D. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute to malignant transformation. Blood 83 (1994) 2780-2786
147. Fenaux P., Lucidarme D., Lai J.L., and Bauters F. Favorable cytogenetic abnormalities in secondary leukemia. Cancer 63 (1989) 2505-2508
148. Pedersen-Bjergaard J., Brondum-Nielsen K., Karle H., and Johansson B. Chemotherapy-related - and late occurring - Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors?. Leukemia 11 (1997) 1571-1574
149. Stark B., Jeison M., Shohat M., et al. Involvement of 11p15 and 2q21q26 9n therapy- related myeloid leukemia (t-ML) in children. Cancer Genet Cytogenet 75 (1994) 11-22
150. Kobayashi H., Arai Y., Hosoda F., et al. Inversion of chromosome 11 inv(11) (p15q22), as a recurring chromosomal aberration associated with de novo and secondary myeloid malignancies: identification of a P1 clone spanning the 11q22 breakpoint. Genes Chromosomes Cancer 19 3 (1997) 150-155
151. Raza-Egilmez S.Z., Jani-Sait S.N., Grossi M., Higgins M.J., Shows T.B., and Apian P.D. NUP98- HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res. 58 (1998) 4269-4273
152. Aria Y., Hosoda F., Kobayashi H., et al. The inv(11) (p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with a putative RNA helicase gene, DDX10. Blood 89 (1997) 3936-3944
153. Nakamura T., Largaespada D.A., Lee M.P., et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by chromosomal translocation t(7;11) (p15;p15) in human myeloid leukemia. Nature Genet 12 (1996) 154-158
154. Borrow J., Shearman A.M., Stanton Jr. V.P., et al. The t(7;11) (p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoporin NUP98 to class I homeoprotein HOXA9. Nature Genet 12 (1996) 159-167
155. Nakamura T., Yamazaki Y., Hatano Y., and Miura I. NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11) (q23;p15). Blood 94 (1999) 741-747
156. Yasuhito A., Hosoda F., Kobayashi H., et al. The inv(11) (p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene NUP98 with the putative RNA helicase gene DDX10. Blood 89 (1997) 3936-3944
157. Ahuja H.G., Felix C.A., and Apian P.D. The t(11;20) (p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in NUP98-TOP1 fusion. Blood 94 (1999) 3258-3261
158. Rowley J.D., and Olney H.J. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer 33 4 (2002) 331-345
159. Mistry A.R., Felix C.A., Whitmarsh R.J., et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N. Engl. J. Med. 352 15 (2005) 1529-1538
160. Gurney J.G., Ross J.A., Wall D.A., Bleyer W.A., Severson R.K., and Robison L.L. Infant cancer in the U.S.: Histology-specific incidence and trends, 1973-1992. J. Pediatr. Hematol./Oncol. 19 (1997) 428-432
161. Felix C.A., Hosier M.R., Slater D.J., et al. MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children. J. Pediatr. Hematol./Oncol. 20 (1998) 299-308
162. Cimino G., Rapanotti M.C., Biondi A., et al. Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. Cancer Res. 57 (1997) 2879-2883
163. Reichel M., Gillert E., Angermuller S., et al. Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL. Oncogene 20 23 (2001) 2900-2907
164. Gillert E., Leis T., Repp R., et al. A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells. Oncogene 18 (1999) 4663-4671
165. Leis T., Repp R., Borkhardt A., et al. A new fingerprint method for sequence analysis of chromosomal translocations at the genomic DNA level. Leukemia 12 5 (1998) 758-763
166. L.J. Raffini, N.-K.V. Cheung, E.F.Rappaport, C.A. Felix, MLL translocation in treatment-related ALL emerged after marrow harvest and before radioimmunotherapy during N7 neuroblastoma treatment. Proc ANR Meeting 2002 2002: Abstract PC-55.
167. Slater D.J., Hilgenfeld E., Rappaport E.F., et al. MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site. Oncogene 21 30 (2002) 4706-4714
168. Megonigal M.D., Rappaport E.F., Jones D.H., et al. t(11;22) (q23;q11.2) in acute myeloid leukemia of infant twins fuses MLL with hCDCrel, a cell division cycle gene in the genomic region of deletion in DiGeorge and velocardiofacial syndromes. Proc. Natl. Acad. Sci. USA 95 (1998) 6413-6418
169. Felix C.A., Kim C.S., Megonigal M.D., et al. Panhandle PCR amplifies genomic translocation breakpoint involving unknown partner gene. Blood 90 (1997) 4679-4686
170. Liang F., Han M., Romanienko P.J., and Jasin M. Homology-directed repair is a major double- strand break repair pathway in mammalian cells. Proc. Natl. Acad. Sci. USA 95 (1998) 5172-5177
171. Blanco J.G., Dervieux T., Edick M.J., et al. Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukaemia. Proc. Natl. Acad. Sci. U S A 98 (2001) 10338-10343
172. Ford A.M., Ridge S.A., Cabrera M.E., et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363 (1993) 358-360
173. Greaves M.F., Maia A.T., Wiemels J.L., and Ford A.M. Leukemia in twins: lessons in natural history. Blood 102 7 (2003) 2321-2333
174. Gale K., Ford A., Repp R., et al. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal bloodspots. Proc. Natl. Acad. Sci. USA 94 (1997) 13950-13954
175. Maia A.T., Koechling J., Corbett R., Metzler M., Wiemels J.L., and Greaves M. Protracted postnatal natural histories in childhood leukemia. Genes Chromosomes Cancer 39 (2004) 335-340
176. Felix C.A., Walker A.H., Lange B.J., et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA 95 22 (1998) 13176-13181
177. Ben-Yehuda D., Krichevsky S., Shafran S., et al. Therapy-related leukemia: Clinical characteristics and analysis of new molecular risk factors in 96 patients. Blood 100 Suppl. l (2002) 324a
178. Bolton J.L., Trush M.A., Penning T.M., Dryhurst G., and Monks T.J. Role of quinones in toxicology. Chem. Res. Toxicol. 13 3 (2000) 135-160
179. Spector L., Xie Y., Robison L., et al. Maternal Diet and Infant Leukemia: The DNA Topoisomerase II Inhibitor Hypothesis: A Report from the Children's Oncology Group. Cancer Epidemiol. Biomarkers Prev. 14 3 (2005) 651-655
180. Adlercreutz H., Yamada T., Wahala K., and Watanabe S. Maternal and neonatal phytoestrogens in Japanese women during birth. Am. J. Obstet. Gynecol. 180 3 Pt l (1999) 737-743
181. Doerge D.R., Churchwell M.I., Chang H.C., Newbold R.R., and Delclos K.B. Placental transfer of the soy isoflavone genistein following dietary and gavage administration to Sprague Dawley rats. Reprod. Toxicol. 15 2 (2001) 105-110
182. Wiemels J.L., Pagnamenta A., Taylor G.M., Eden O.B., Alexander F.E., and Greaves M.F. A lack of a functional NAD (P)H:Quinone Oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res. 59 (1999) 4095-4099
183. Smith M.T., Wang Y., Skibola C.F., et al. Low NAD (P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 100 13 (2002) 4590-4593
184. McDonald T.A., Holland N.T., Skibola C., Duramad P., and Smith M.T. Hypothesis: phenol and hydroquinone derived mainly from diet and gastrointestinal flora activity are causal factors in leukemia. Leukemia 15 (2001) 10-20
185. de la Chica R., Ribas I., Giraldo J., Egozcue J., and Fuster C. Chromosomal Instability in amniocytes from fetuses of mothers who smoke. JAMA 293 (2005) 1212-1222
186. Yin S.N., Hayes R.B., Linet M.S., et al., Benzene Study Group. An expanded cohort study of cancer among benzene- exposed workers in China. Environ. Health Perspect 104 Suppl 6 (1996) 1339-1341
187. Hayes R.B., Yin S.N., Dosemeci M., et al., Chinese Academy of Preventive Medicine-National Cancer Institute Benzene Study Group. Benzene and the dose-related incidence of hematologic neoplasms in China. J. Natl. Cancer Inst. 89 14 (1997) 1065-1071
188. Rothman N., Smith M.T., Hayes R.B., et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 57 14 (1997) 2839-2842
189. Kim S.Y., Choi J.K., Cho Y.H., Chung E.J., Paek D., and Chung H.W. Chromosomal aberrations in workers exposed to low levels of benzene: association with genetic polymorphisms. Pharmacogenetics 14 7 (2004) 453-463
190. Smith M.T., Zhang L., Wang Y., et al. Increased translocations and aneusomy in chromosomes 8 and 21 among workers exposed to benzene. Cancer Res. 58 10 (1998) 2176-2181
191. Sole F., Caballin M.R., Coll M.D., Woessner S., and Egozcue J. Acute lymphoblastic leukemia with t(4;11) in a patient previously exposed to a carcinogen. Cancer Genet Cytogenet 49 1 (1990) 133-136
192. Felix C.A., Lange B.J., Hosier M.R., Fertala J., and Bjornsti M.-A. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res. 55 (1995) 4287-4292
193. Lovett B.D., Strumberg D., Blair I.A., et al. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 40 5 (2001) 1159-1170
194. Bromberg K.D., Burgin A.B., and Osheroff N. A two-drug model for etoposide action against human topoisomerase II alpha. J. Biol. Chem. 278 9 (2003) 7406-7412
195. Pohlhaus J.R., and Kreuzer K.N. Norfloxacin-induced DNA gyrase cleavage complexes block Escherichia coli replication forks, causing double-stranded breaks in vivo. Mol. Microbiol. 56 6 (2005) 1416-1429
196. Frost B., Eksborg S., Bjork O., et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med. Pediatr. Oncol. 38 5 (2002) 329-337
197. Pommier Y., Capranico G., Orr A., and Kohn K.W. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Res. 19 (1991) 5973-5980
198. Pommier Y., Kohn K.W., Capranico G., and Jaxel C. Base sequence selectivity of topoisomerase inhibitors suggests a common model for drug action. Mol. Biol. DNA Topo (1993) 215-227
199. Pommier Y., Orr A., Kohn K.W., and Riou J.-F. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Cancer Res. 52 (1992) 3125-3130
200. Capranico G., Kohn K.W., and Pommier Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res. 18 (1990) 6611-6619
201. Zheng N., Felix C.A., Pang S., et al. Plasma Etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with Etoposide. Clin. Cancer Res. 10 9 (2004) 2977-2985
202. Reichel M., Gillert E., Nilson I., et al. Fine structure of translocation breakpoints in leukemic blasts with chromosomal translocation t(4;11): the DNA damage-repair model of translocation. Oncogene 17 (1998) 3035-3044
203. Reichel M., Gillert E., Breitenlohner I., et al. Rapid isolation of chromosomal breakpoints from patients with t(4;11) acute lymphoblastic leukemia: implications for basic and clinical research. Cancer Res. 59 (1999) 3357-3362
204. Andersen A.H., Christiansen K., Zechiedrich E.L., Jensen P.S., Osheroff N., and Westergaard O. Strand specificity of the topoisomerase II mediated double-stranded DNA cleavage reaction. Biochemistry 28 15 (1989) 6237-6244
205. Lee M.P., and Hsieh T. Incomplete reversion of double stranded DNA cleavage mediated by Drosophila topoisomerase II: formation of single stranded DNA cleavage complex in the presence of an anti-tumor drug VM26. Nucleic Acids Res. 20 19 (1992) 5027-5033
206. Muller M.T., Spitzner J.R., DiDonato J.A., Mehta V.B., and Tsutsui K. Single-strand DNA cleavages by eukaryotic topoisomerase II. Biochemistry 27 22 (1988) 8369-8379
207. Zechiedrich E.L., Christiansen K., Andersen A.H., Westergaard O., and Osheroff N. Double- stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate. Biochemistry 28 15 (1989) 6229-6236
208. Pommier Y.G., Fesen M.R., and Goldwasser F. Topoisomerase II Inhibitors: The Epipodophyllotoxins, m-AMSA, and the Ellipticine derivatives. In: Chabner B.A., and Longo D.L. (Eds). Cancer Chemotherapy and Biotherapy. second ed. (1996), Lippincott-Raven, Philadelphia 435-461
209. Reed Williams W.L., Slater D.J., Rappaport E.F., et al. Genomic cloning and in vitro DNA topoisomerase II cleavage assays support in utero DNA topoisomerase II-mediated DNA damage in MLL translocation in AML of infant twins. Blood 98 Suppl. l (2001) 561a
210. C. Kolaris, D.J. Slater, A. Sechser-Perl, E.F. Rappaport, N. Osheroff, C.A. Felix,. Topoisomerase II poisons and the etiology of acute leukemia in infants, in: Proc 47th Annual Meeting American Society of Hematology 2005.
211. Hong G., and Kreuzer K.N. Endonuclease cleavage of blocked replication forks: An indirect pathway of DNA damage from antitumor drug-topoisomerase complexes. Proc. Natl. Acad. Sci. USA 100 9 (2003) 5046-5051
212. Byl J.A., Cline S.D., Utsugi T., Kobunai T., Yamada Y., and Osheroff N. DNA Topoisomerase II as the Target for the Anticancer Drug TOP-53: mechanistic basis for drug action. Biochemistry 40 3 (2001) 712-718
213. Libura J., Slater D.J., Felix C.A., and Richardson C. t-AML-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Blood (2004)
214. Betti C.J., Villalobos M.J., Diaz M.O., and Vaughan A.T.M. Apoptotic triggers initiate translocations within the MLL gene involving the nonhomologous end joining reppair system. Cancer Res. 61 (2001) 4550-4555
215. Sim S.-P., and Liu L.F. Nucleolytic cleavage of the Mixed Lineage Leukemia breakpoint cluster region during apoptosis. J. Biol. Chem. 276 (2001) 31590-31595
216. Betti C.J., Villalobos M.J., Diaz M.O., and Vaughan A.T. Apoptotic stimuli initiate MLL-AF9 translocations that are transcribed in cells capable of division. Cancer Res. 63 6 (2003) 1377-1381
217. Apian P.D., Chervinsky D.S., Stanulla M., and Burhans W.C. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 87 7 (1996) 2649-2658
218. Stanulla M., Wang J., Chervinsky D.S., Thandla S., and Apian P.D. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol. Cell Biol. 17 7 (1997) 4070-4079
219. Capranico G., Jaxel C., Roberge M., Kohn K.W., and Pommier Y. Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase II in reconstituted simian virus 40 chromatin. Nucleic Acids Res. 18 (1990) 4553-4559